Skip to main content

Effect of NF-κB Signaling on Apoptosis in Chronic Inflammation-Associated Carcinogenesis

Buy Article:

$55.00 plus tax (Refund Policy)

The causal relationship between inflammation and cancer has been documented for sometime, but its molecular nature remains ill defined. Increasing evidence suggested that inflammatory microenvironment in and around tumors is an indispensable participant in the neoplastic process. High level of free radicals produced during inflammation significantly induces DNA damage while evading apoptosis, a hallmark of cancer, reduces the capability of tissues to eliminate damaged cells. Therefore, the mechanism by which inflammation affects the apoptosis pathway is crucial to understand inflammation- associated carcinogenesis. Nuclear factor-κB (NF-κB), a transcriptional factor, plays an important role in the regulation of inflammatory responses. NF-κB signaling, which can be activated by diverse stimuli including proinflammatory cytokines, infectious agents and cellular stresses, has been shown to be involved in carcinogenesis and resistance to multiple drug therapy. In this review, we focus on the role of NF-κB signaling on the apoptotic effect in inflammationassociated carcinogenesis. These insights may help us to consider the role of NF-κB in inflammation and cancer and further on as a target of drugs for the prevention and treatment of these diseases.

No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Apoptosis; NF-κB; carcinogenesis; inflammation; p53

Document Type: Research Article

Publication date: 2010-09-01

More about this publication?
  • Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
    Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
    As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more